- Thinly traded micro cap Cardiome Pharma (CRME) is off 42% premarket on robust volume in response to its announcement that its has priced its public offering of 10M shares of common stock at $3.00 per share. Underwriters over-allotment is an additional 1.5M shares. Closing date is July 29.
- Net proceeds will fund the in-licensing of dalbavancin, including milestone payments related to pricing reimbursement and launches, and general corporate purposes.